Clinical trials: APL
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
This phase I trial is studying the safety and potential efficacy of infusing non-human leukocyte antigen (HLA) matched ex vivo expanded cord blood progenitors following treatment with clofarabine and cytarabine for patients with…
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT01031368
- Testing
- cytarabine, clofarabine, filgrastim
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Nohla Therapeutics, Inc.
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of lenalidomide when given together with cytarabine and idarubicin in treating patients with acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
- Trial name
- NCT01132586
- Testing
- Lenalidomide, Cytarabine, Idarubicin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult
Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice
Prospective, multicenter study for the non-inferiority assessment of RAMD compared to GSS in determining the prognostic risk category according to ELN2022 for newly diagnosed AML patients on blood samples.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult, Acute Promyelocytic Leukemia
- Trial name
- RAMD (NCT07867704)
- Testing
- Bone marrow or peripheral blood withdrawal for test comparison
- Volunteers
- 75 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Cancer
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
RATIONALE: Giving itraconazole or fluconazole may be effective in preventing infections in patients undergoing peripheral stem cell or bone marrow transplantation.
- Trial name
- NCT00003883
- Testing
- fluconazole, itraconazole
- Where
- 2 sites in United States
- Volunteers
- 578 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to determine the activity of tamibarotene in participants with relapsed/refractory (R/R) AML (administered as a monotherapy or in combination with azacitidine), R/R higher-risk MDS (HR-MDS)…
- Trial name
- NCT02807558
- Testing
- Tamibarotene, Azacitidine, Daratumumab
- Where
- 26 sites in United States, France
- Volunteers
- 155 people
- Sponsor
- Syros Pharmaceuticals
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase II trial is studying how well romidepsin works in treating patients with relapsed or refractory acute myeloid leukemia.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00062075
- Testing
- romidepsin
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
This phase I trial is studying the side effects and best dose of belinostat when given together with azacitidine in treating patients with advanced hematologic cancers or other diseases.
- Conditions
- Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
- Trial name
- NCT00351975
- Testing
- Belinostat, Azacitidine, Laboratory Biomarker Analysis
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
- Conditions
- Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
- Trial name
- QUATRO-APL (NCT07504458)
- Testing
- QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA
- Where
- 36 sites in United States, France and 3 more
- Volunteers
- 150 people
- Sponsor
- Quetzal Therapeutics
Geographic Atrophy Secondary to Age-related Macular Degeneration
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients…
- Trial name
- NCT07215390
- Testing
- APL-3007, pegcetacoplan (APL-2)
- Where
- 78 sites in United States
- Volunteers
- 240 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Leukemia
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00492856
- Testing
- mercaptopurine, methotrexate, tretinoin
- Where
- 210 sites in United States
- Volunteers
- 105 people
- Sponsor
- SWOG Cancer Research Network
Bone Marrow Ablation, Leukemia
High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002567
- Testing
- filgrastim, etoposide, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
Several groups, especially the PETHEMA group (in their LPA96 and 99 trials), obtained low relapse rates in newly diagnosed Acute Promyelocytic Leukemia (APL) patients by combining ll-transretinoic acid (ATRA) and anthracyclines…
- Trial name
- Ara-C (NCT01191541)
- Testing
- DNR:, Ara-c
- Where
- 2 sites in China
- Volunteers
- 65 people
- Sponsor
- Xiaofan Zhu
Leukemia, Promyelocytic, Acute
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner. Risk factors are age and white-blood-cell (WBC)-count at diagnosis.
- Trial name
- NCT00180128
- Testing
- all-trans retinoid acid, idarubicin, mitoxantrone
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Technische Universität Dresden
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This randomized phase II trial studies how well giving tacrolimus and mycophenolate mofetil (MMF) with or without sirolimus works in preventing acute graft-versus-host disease (GVHD) in patients undergoing donor stem cell…
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic Lymphocytic Leukemia, Refractory Plasma Cell Myeloma
- Trial name
- NCT00105001
- Testing
- Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 210 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Promyelocytic Leukemia, Pregnancy
Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy
The GIMEMA FOUNDATION promotes an observational (retrospective) study on number and outcome of pregnancy in childbearing age female patients treated with chemotherapy for APL.
- Trial name
- APL0511 (NCT01472107)
- Where
- 36 sites in Italy
- Volunteers
- 69 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
RATIONALE: Bone marrow from donors may be able to treat patients with severe aplastic anemia and patients whose bodies have rejected previous bone marrow transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00005852
- Testing
- anti-thymocyte globulin, filgrastim, muromonab-CD3
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia
This randomized clinical trial studies liposomal cytarabine-daunorubicin CPX-351 in treating patients with untreated myelodysplastic syndrome or acute myeloid leukemia.
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
- Trial name
- NCT01804101
- Testing
- Laboratory Biomarker Analysis, Liposomal Cytarabine-Daunorubicin CPX-351
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Promyelocytic Leukemia
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
SY-2101 is being studied as a treatment for participants with a type of leukemia called acute promyelocytic leukemia (APL). SY-2101 is an oral formulation of a drug called arsenic trioxide (ATO).
- Trial name
- NCT04996030
- Testing
- SY-2101, Arsenic Trioxide
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Syros Pharmaceuticals
Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
Phase I trial to study the effectiveness of SB-715992 in treating patients who have acute leukemia, chronic myelogenous leukemia, or advanced myelodysplastic syndromes.
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00098826
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
This randomized phase I trial is studying the side effects and best dose of two different schedules of sorafenib in treating patients with refractory or relapsed acute leukemia, myelodysplastic syndromes, or blastic phase chronic…
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
- Trial name
- NCT00217646
- Testing
- Sorafenib Tosylate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)